期刊文献+

皮肤晚期糖基化终末产物与2型糖尿病合并下肢动脉病变的相关性 被引量:5

Correlation research between skin advanced glycation end products and peripheral artery disease in type 2 diabetes mellitus
下载PDF
导出
摘要 目的分析2型糖尿病伴下肢动脉病变患者皮肤晚期糖基化终末产物(AGEs)水平变化及其临床意义。方法 111例2型糖尿病患者,依据ABI(ankle-brachial index,踝肱指数)不同将其分为DM1组(0.9≤ABI≤1.3,n=46)、PAD1组(0.5≤ABI<0.9,n=51)、PAD2组(ABI<0.5,n=14),正常对照组35例,为同期体检健康人群。分别测定皮肤AGEs、糖化血红蛋白、ABI等指标。结果与正常对照组相比,糖尿病患者皮肤AGEs水平明显升高(P<0.05);与DM1组相比,PAD组皮肤AGEs水平明显增高(P<0.05),且PAD2组皮肤AGEs水平明显高于PAD1组。结论 2型糖尿病患者皮肤AGEs水平升高并可能参与了糖尿病下肢血管病变的发生,可以作为反映糖尿病下肢血管病变程度的指标之一。 Objective To analyze the level changes and clinical significance of skin advanced glycation end products (SAGEs) in type 2 diabetes with peripheral artery diseases. Methods According to the ankle - brachial index, 111 patients with type 2 diabetes were di- vided into three groups:DM1 group (0.9≤ABI≤1. 3 ,n =46) ,PAD1 group (0.5 ≤ABI 〈0.9,n =51 ) ,and PAD2 group ( ABI 〈0.5 ,n = 14) ;35 cases of normal control group were selected from the medical center for healthy people. SAGEs, glycated hemoglobin (HbA1 c), ABI and other index were detected. Results Compared with normal control group, SAGEs level was obviously increased in patients with diabetes (P 〈 0.05 ) , compared with DM1 group, the level of SAGEs also increased in PAD group, and the level of SAGEs in PAD2 group was higher than that in PAD1 group. Conclusion The SAGEs level was obviously increased in patients with type 2 diabetes ,which may be involved in the pathogenesis of PAD, and could be used as an index for evaluating the severity of PAD.
出处 《安徽医学》 2014年第1期16-18,共3页 Anhui Medical Journal
基金 安徽省年度重点科研项目(11070403035)
关键词 下肢动脉病变 2型糖尿病 晚期糖基化终末产物 Peripheral artery disease Type 2 diabetes Advanced glycation end products
  • 相关文献

参考文献10

二级参考文献26

  • 1周陵,陈绍良,叶飞,罗俊,林松,单守杰,蒋伏平,段宝祥.冠心病患者血清脂联素与C-反应蛋白关系的研究[J].中国综合临床,2006,22(5):400-401. 被引量:11
  • 2Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation endproducts in patients with diabetic nephropathy N Eng. Med, 1991,325:836-842.
  • 3Vlassara H. Protein glycation in the kidney:role in diabetes and aging. Kidney Int, 1996,49 : 1795 , 1840.
  • 4Ono Y, Aoki S, Ohnishi K, et al. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complica-tions. Diabetes Care, 1998, 21: 1021-1027.
  • 5Sima A, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia, 1999, 42: 773-788.
  • 6Kiuchi K, Nejima J, Takano T, et al. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart, 2001, 85 : 87 -91.
  • 7Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes, 1997, 46 ( suppl 2) : s19-s25.
  • 8Wautier JL,Schmidt AM.Protein glycation:a firm link to endothelial cell dysfunction[J].Circ Res,2004,95(3):233-238.
  • 9Imanaga Y,Sakata N,Takebayashi S,et al.In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques[J].Atherosclerosis,2000,150(2):343-355.
  • 10Zieman S,Kass D.Advanced glycation end product cross-linking:pathophysiologic role and therapeutic target in cardiovascular disease[J].Congest Heart Fail,2004,10(3):144-149.

共引文献41

同被引文献41

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部